Long-term neuropsychiatric disorders on efavirenz-based approaches : Quality of life, psychologic issues, and adherenceFUMAZ, Carmina R; MUNOZ-MORENO, Jose A; MOLTO, José et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 38, Num 5, pp 560-565, issn 1525-4135, 6 p.Article

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 functionDI IULIO, Julia; FAYET, Aurélie; EAP, Chin B et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 4, pp 300-309, issn 1744-6872, 10 p.Article

Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy SubjectsROBERTSON, Sarah M; MALDARELLI, Frank; NATARAJAN, Ven et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 5, pp 513-519, issn 1525-4135, 7 p.Article

Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenzMOGATLE, Seloi; SKINNER, Michael; MILLS, Edward et al.SAMJ. South African medical journal. 2008, Vol 98, Num 12, pp 945-949, issn 0256-9574, 5 p.Article

Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral TherapyGERETTI, Anna Maria; FOX, Zoe V; BOOTH, Clare L et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 5, pp 569-573, issn 1525-4135, 5 p.Conference Paper

Bioequivalence of efavirenz /emtricitabine /tenofovir disoproxil fumarate single-tablet regimenMATHIAS, Anita A; HINKLE, John; MENNING, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 167-173, issn 1525-4135, 7 p.Article

Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited ClinicsAMOROSO, Anthony; ETIENNE-MESUBI, Martine; EDOZIEN, Anthony et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 3, pp 314-320, issn 1525-4135, 7 p.Article

Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients : The role of genderSMITH, Colette J; SABIN, Caroline A; YOULE, Mike S et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 1, pp 62-67, issn 1525-4135, 6 p.Article

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7ROTGER, Margalida; SAUMOY, Maria; KUNLIN ZHANG et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 10, pp 885-890, issn 1744-6872, 6 p.Article

Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy VolunteersLIUSHENG HUANG; PARIKH, Sunil; ROSENTHAL, Philip J et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 3, pp 310-316, issn 1525-4135, 7 p.Article

PharmGKB summary: very important pharmacogene information for CYP2B6THORN, Caroline F; LAMBA, Jatinder K; LAMBA, Vishal et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 8, pp 520-523, issn 1744-6872, 4 p.Article

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacyVAN LETH, F; KAPPELHOFF, B. S; WIT, F. W et al.AIDS research and human retroviruses. 2006, Vol 22, Num 3, pp 232-239, issn 0889-2229, 8 p.Article

Long-Term Assessment of Didanosine, Lamivudine, and Efavirenz in Antiretroviral-Naive Patients : 3-Year Follow-UpSANTOS, Jesus; PALACIOS, Rosario; LOZANO, Fernando et al.AIDS research and human retroviruses. 2008, Vol 24, Num 1, pp 24-26, issn 0889-2229, 3 p.Article

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy VolunteersBOFFITO, Marta; JACKSON, Akil; LAMORDE, Mohammed et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 222-227, issn 1525-4135, 6 p.Article

Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz DiscontinuationsVAN LUIN, Matthijs; GRAS, Luuk; RICHTER, Clemens et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 240-245, issn 1525-4135, 6 p.Conference Paper

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infectionDYBUL, Mark; NIES-KRASKE, Elizabeth; METCALF, Julia A et al.The Journal of infectious diseases. 2004, Vol 189, Num 11, pp 1974-1982, issn 0022-1899, 9 p.Article

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1-infected PatientsEDEN, Arvid; ANDERSSON, Lars-Magnus; TUNBÄCK, Petra et al.AIDS research and human retroviruses. 2010, Vol 26, Num 5, pp 533-540, issn 0889-2229, 8 p.Article

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenzBORROTO-ESODA, Katyna; WATERS, Joshua M; BAE, Andrew S et al.AIDS research and human retroviruses. 2007, Vol 23, Num 8, pp 988-995, issn 0889-2229, 8 p.Article

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patientsCICCARELLI, N; FABBIANI, M; DI GIAMBENEDETTO, S et al.Neurology. 2011, Vol 76, Num 16, pp 1403-1409, issn 0028-3878, 7 p.Article

Prevalence of Etravirine-Associated Mutations in Clinical Samples With Genotypic Resistance to Nevirapine and Efavirenz in Brazilian ClinicsMARTINS, Angelica N; ARRUDA, Monica B; ALEIXO, Agdemir W et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 57, issn 1525-4135, S193-S196, SUP3Article

Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to EtravirineMANOSUTHI, Weerawat; BUTLER, David M; CHANTRATITA, Wasun et al.AIDS research and human retroviruses. 2010, Vol 26, Num 6, pp 609-611, issn 0889-2229, 3 p.Article

Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function: A Randomized, Controlled TrialGUPTA, Samir K; DEMING MI; MOE, Sharon M et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 64, Num 3, pp 279-283, issn 1525-4135, 5 p.Article

Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267DOOLEY, Kelly E; PARK, Jeong-Gun; QASBA, Sonia et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 5, pp 455-462, issn 1525-4135, 8 p.Article

Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in UgandaFILLEKES, Quirine; NATUKUNDA, Eva; WALKER, A. Sarah et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 4, pp 392-398, issn 1525-4135, 7 p.Article

Efavirenz in Human Breast Milk, Mothers', and Newborns' PlasmaSCHNEIDER, Serge; PELTIER, Alexandra; GRAS, Alain et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 48, Num 4, pp 450-454, issn 1525-4135, 5 p.Article